Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,836
archived clinical trials in
Leukemia

S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Saint Luke's Cancer Institute at Saint Luke's Hospital
1340
mi
from 91732
Kansas City, MO
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Saint Luke's Cancer Institute at Saint Luke's Hospital
1340
mi
from 91732
Kansas City, MO
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Parvin Radiation Oncology
1351
mi
from 91732
Liberty, MO
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Parvin Radiation Oncology
1351
mi
from 91732
Liberty, MO
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Saint Joseph Oncology, Incorporated
1334
mi
from 91732
Saint Joseph, MO
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Saint Joseph Oncology, Incorporated
1334
mi
from 91732
Saint Joseph, MO
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
CCOP - Montana Cancer Consortium
951
mi
from 91732
Billings, MT
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
CCOP - Montana Cancer Consortium
951
mi
from 91732
Billings, MT
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Billings Clinic - Downtown
948
mi
from 91732
Billings, MT
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Billings Clinic - Downtown
948
mi
from 91732
Billings, MT
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Great Falls Clinic - Main Facility
990
mi
from 91732
Great Falls, MT
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Great Falls Clinic - Main Facility
990
mi
from 91732
Great Falls, MT
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Montana Cancer Specialists at Montana Cancer Center
907
mi
from 91732
Missoula, MT
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Montana Cancer Specialists at Montana Cancer Center
907
mi
from 91732
Missoula, MT
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Wayne Memorial Hospital, Incorporated
2258
mi
from 91732
Goldsboro, NC
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Wayne Memorial Hospital, Incorporated
2258
mi
from 91732
Goldsboro, NC
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
1959
mi
from 91732
Columbus, OH
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
1959
mi
from 91732
Columbus, OH
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
AnMed Cancer Center
2008
mi
from 91732
Anderson, SC
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
AnMed Cancer Center
2008
mi
from 91732
Anderson, SC
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
CCOP - Upstate Carolina
2043
mi
from 91732
Spartanburg, SC
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
CCOP - Upstate Carolina
2043
mi
from 91732
Spartanburg, SC
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Columbia Basin Hematology
840
mi
from 91732
Kennewick, WA
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Columbia Basin Hematology
840
mi
from 91732
Kennewick, WA
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
1745
mi
from 91732
Green Bay, WI
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
1745
mi
from 91732
Green Bay, WI
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Green Bay Oncology, Limited at St. Mary's Hospital
1744
mi
from 91732
Green Bay, WI
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Green Bay Oncology, Limited at St. Mary's Hospital
1744
mi
from 91732
Green Bay, WI
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
St. Mary's Hospital Medical Center - Green Bay
1744
mi
from 91732
Green Bay, WI
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
St. Mary's Hospital Medical Center - Green Bay
1744
mi
from 91732
Green Bay, WI
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Green Bay Oncology, Limited - Oconto Falls
1745
mi
from 91732
Oconto Falls, WI
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Green Bay Oncology, Limited - Oconto Falls
1745
mi
from 91732
Oconto Falls, WI
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Green Bay Oncology, Limited - Sturgeon Bay
1780
mi
from 91732
Sturgeon Bay, WI
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Green Bay Oncology, Limited - Sturgeon Bay
1780
mi
from 91732
Sturgeon Bay, WI
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Union Hospital of Cecil County
2341
mi
from 91732
Elkton, MD
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Union Hospital of Cecil County
2341
mi
from 91732
Elkton, MD
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Regions Hospital - Cancer Care Center
1517
mi
from 91732
Saint Paul, MN
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Regions Hospital - Cancer Care Center
1517
mi
from 91732
Saint Paul, MN
Click here to add this to my saved trials
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia
A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  12/27/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
2277
mi
from 91732
Bethesda, MD
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia
A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 12/27/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
2277
mi
from 91732
Bethesda, MD
Click here to add this to my saved trials
Pre and Post Treatment Metabolomic Analysis of Leukemia: A Translational Clinical Trial of the Brown Cancer Center
PRE AND POST TREATMENT METABOLOMIC ANALYSIS OF LEUKEMIA: A Translational Clinical Trial of the Brown Cancer Center
Status: Enrolling
Updated:  12/27/2017
James Graham Brown Cancer Center, University of Louisville
1813
mi
from 91732
Louisville, KY
Pre and Post Treatment Metabolomic Analysis of Leukemia: A Translational Clinical Trial of the Brown Cancer Center
PRE AND POST TREATMENT METABOLOMIC ANALYSIS OF LEUKEMIA: A Translational Clinical Trial of the Brown Cancer Center
Status: Enrolling
Updated: 12/27/2017
James Graham Brown Cancer Center, University of Louisville
1813
mi
from 91732
Louisville, KY
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Phoenix Children's Hospital
345
mi
from 91732
Phoenix, AZ
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Phoenix Children's Hospital
345
mi
from 91732
Phoenix, AZ
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Jonathan Jaques Children'S Cancer Center
23
mi
from 91732
Long Beach, CA
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Jonathan Jaques Children'S Cancer Center
23
mi
from 91732
Long Beach, CA
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Children's Hospital of Orange County
21
mi
from 91732
Orange, CA
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Children's Hospital of Orange County
21
mi
from 91732
Orange, CA
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Children'S Hospital
825
mi
from 91732
Aurora, CO
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Children'S Hospital
825
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Children's Hospital of Chicago
1729
mi
from 91732
Chicago, IL
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Children's Hospital of Chicago
1729
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Dana Faber Cancer Institute
2578
mi
from 91732
Boston, MA
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Dana Faber Cancer Institute
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Oregon Health and Science University
827
mi
from 91732
Portland, OR
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Oregon Health and Science University
827
mi
from 91732
Portland, OR
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Children's Hospital of Philadelphia
2375
mi
from 91732
Philadelphia, PA
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Children's Hospital of Philadelphia
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Texas Children'S Cancer Center
1357
mi
from 91732
Houston, TX
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Texas Children'S Cancer Center
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Seattle Children's
966
mi
from 91732
Seattle, WA
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Seattle Children's
966
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Memorial Sloan Kettering Cancer Center
2434
mi
from 91732
New York, NY
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Memorial Sloan Kettering Cancer Center
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Children's Hospital of Pittsburgh
2121
mi
from 91732
Pittsburgh, PA
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Children's Hospital of Pittsburgh
2121
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Local Institution
6113
mi
from 91732
Bunos Aires,
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Local Institution
6113
mi
from 91732
Bunos Aires,
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Children's Healthcare of Atlanta - Egleston
1922
mi
from 91732
Atlanta, GA
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Children's Healthcare of Atlanta - Egleston
1922
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated:  1/4/2018
Stephen D. Hassenfeld Children'S Center
2432
mi
from 91732
New York, NY
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Enrolling
Updated: 1/4/2018
Stephen D. Hassenfeld Children'S Center
2432
mi
from 91732
New York, NY
Click here to add this to my saved trials
Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers
Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan
Status: Enrolling
Updated:  1/5/2018
University of California Davis Cancer Center
363
mi
from 91732
Sacramento, CA
Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers
Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan
Status: Enrolling
Updated: 1/5/2018
University of California Davis Cancer Center
363
mi
from 91732
Sacramento, CA
Click here to add this to my saved trials
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
Status: Enrolling
Updated:  1/8/2018
University of Texas M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
Status: Enrolling
Updated: 1/8/2018
University of Texas M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
A Phase 1/2 Trial Evaluating Treatment of Emergent Graft Versus Host Disease (GvHD) With AP1903 After Planned Donor Infusions (DLIs) of T-cells Genetically Modified With the iCasp9 Suicide Gene in Patients With Hematologic Malignancies
Status: Enrolling
Updated:  1/9/2018
University of Texas M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
A Phase 1/2 Trial Evaluating Treatment of Emergent Graft Versus Host Disease (GvHD) With AP1903 After Planned Donor Infusions (DLIs) of T-cells Genetically Modified With the iCasp9 Suicide Gene in Patients With Hematologic Malignancies
Status: Enrolling
Updated: 1/9/2018
University of Texas M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
A Feasibility Study of Prophylactic White Blood Cell Transfusions
A Feasibility Study of White Blood Cell Transfusion for the Prevention of Infection in Acute Myelogenous Leukemia Patients Undergoing Front-Line or First Salvage Induction Therapy
Status: Enrolling
Updated:  1/10/2018
University of Texas M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
A Feasibility Study of Prophylactic White Blood Cell Transfusions
A Feasibility Study of White Blood Cell Transfusion for the Prevention of Infection in Acute Myelogenous Leukemia Patients Undergoing Front-Line or First Salvage Induction Therapy
Status: Enrolling
Updated: 1/10/2018
University of Texas M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia
Phase I/II Study of Decitabine (DAC) Followed by Clofarabine, Idarubicin, and Cytarabine (CIA) in Acute Leukemia
Status: Enrolling
Updated:  1/17/2018
University of Texas M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia
Phase I/II Study of Decitabine (DAC) Followed by Clofarabine, Idarubicin, and Cytarabine (CIA) in Acute Leukemia
Status: Enrolling
Updated: 1/17/2018
University of Texas M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
T Cell-Reduced Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplantation With Pentostatin and Low-Dose Total Body Irradiation
Status: Enrolling
Updated:  1/22/2018
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
1289
mi
from 91732
Omaha, NE
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
T Cell-Reduced Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplantation With Pentostatin and Low-Dose Total Body Irradiation
Status: Enrolling
Updated: 1/22/2018
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
1289
mi
from 91732
Omaha, NE
Click here to add this to my saved trials
An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)
An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)
Status: Enrolling
Updated:  1/23/2018
University of Texas M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)
An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)
Status: Enrolling
Updated: 1/23/2018
University of Texas M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia
A Phase II Study of Gemcitabine/ Mitoxantrone in Patients With Acute Myeloid Leukemia in First Relapse
Status: Enrolling
Updated:  1/24/2018
Duke Comprehensive Cancer Center
2202
mi
from 91732
Durham, NC
Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia
A Phase II Study of Gemcitabine/ Mitoxantrone in Patients With Acute Myeloid Leukemia in First Relapse
Status: Enrolling
Updated: 1/24/2018
Duke Comprehensive Cancer Center
2202
mi
from 91732
Durham, NC
Click here to add this to my saved trials
Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia
A Phase II Study of Gemcitabine/ Mitoxantrone in Patients With Acute Myeloid Leukemia in First Relapse
Status: Enrolling
Updated:  1/24/2018
Cleveland Clinic Taussig Cancer Center
2033
mi
from 91732
Cleveland, OH
Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia
A Phase II Study of Gemcitabine/ Mitoxantrone in Patients With Acute Myeloid Leukemia in First Relapse
Status: Enrolling
Updated: 1/24/2018
Cleveland Clinic Taussig Cancer Center
2033
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant
Adjustment to Illness by Survival Rates in Allogeneic Bone Marrow Transplant (BMT): The Relative Importance of Lay Care-Partner Support
Status: Enrolling
Updated:  1/25/2018
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
2036
mi
from 91732
Cleveland, OH
Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant
Adjustment to Illness by Survival Rates in Allogeneic Bone Marrow Transplant (BMT): The Relative Importance of Lay Care-Partner Support
Status: Enrolling
Updated: 1/25/2018
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
2036
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Paricalcitol in Treating Patients With Myelodysplastic Syndrome
A Phase II Trial Of Paricalcitol In Myelodysplastic Syndromes
Status: Enrolling
Updated:  1/25/2018
Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center
13
mi
from 91732
Los Angeles, CA
Paricalcitol in Treating Patients With Myelodysplastic Syndrome
A Phase II Trial Of Paricalcitol In Myelodysplastic Syndromes
Status: Enrolling
Updated: 1/25/2018
Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
Hyper-CVAD With Liposomal Vincristine (Hyper-CMAD) in Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  1/26/2018
University of Texas M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
Hyper-CVAD With Liposomal Vincristine (Hyper-CMAD) in Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 1/26/2018
University of Texas M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)
An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)
Status: Enrolling
Updated:  2/1/2018
University of Texas M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)
An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)
Status: Enrolling
Updated: 2/1/2018
University of Texas M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials